Alnylam (ALNY) was downgraded to equal-weight from overweight at Morgan Stanley. $36 price target, given the failure of Revusiran, Morgan Stanley said.
Blackhawk Network (HAWK) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $34 price target. Conversion to chip-based cards is taking longer than expected, analysts said.